Browse by Medical Category
Accepting New Patients
Adam S. Feldman, MD, MPH, is a urologist at the Massachusetts General Hospital Department of Urology. He specializes in the treatment of cancer and related research.
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Adam S. Feldman is a faculty member and Urologic Oncologist in the Department of Urology at Massachusetts General Hospital, and is Director of the Combined Harvard Urologic Oncology Fellowship. He completed his residency in urology in 2006 and subsequently completed his fellowship in urologic oncology in June 2008. Dr. Feldman focuses his clinical practice in the treatment of genitourinary cancers, using laparoscopic, endoscopic, and open techniques. He focuses his research interests on translational and clinical research in kidney, prostate and bladder cancers. He has received a Prostate Cancer Foundation Young Investigator Award for his work in novel biomarkers in prostate cancer and has been awarded a Physician Research Training Award by the Department of Defense. He is a co-PI on a Department of Defense Synergistic Idea Development Award on the development of conditionally reprogrammed cells in prostate cancer and is a co-investigator on an National Institutes of Health RO1 on metabolomic imaging in prostate cancer. In addition to his translational research work in genitourinary cancer biomarkers, he has worked to develop clinical databases in active surveillance in prostate cancer, use of imaging and fusion biopsy in prostate cancer, surgical and ablative treatments for renal cell carcinoma, and renal mass biopsy.
Learn more about Dr. Feldman
View my most recent publications at PubMed
Feldman AS, Banyard J, Wu C-L, et al. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 2009;15(3):1024-31.
Kaufman DS, Shipley WU, Feldman AS. Bladder Cancer. The Lancet. 2009; 374(9685):239-49.
Feldman AS and Dahl DM. , 2006. June, 2-6, 2006. Laparoscopic Radical Prostatectomy. US Oncological Disease 2006. 2006: pp. 56-58.
Feldman AS, McDougal WS, Harisinghani MG. The potential of nanoparticle-enhanced imaging. The Journal of Urologic Oncology, Seminar Section. 2008;26(1):65-73.
Feldman AS, Daha AK, Osbourne AL, et al. Case-matched analysis of radiofrequency ablation vs. open and laparoscopic partial nephrectomy: What is the effect on GFR? Accepted for presentation at the ASCO GU Cancer Symposium, 2010.
About one in seven men will be affected by prostate cancer in their lifetime. Massachusetts General Hospital urologists share updates on prostate cancer screening and treatments.
Active surveillance (AS) has become an accepted way to manage prostate cancer in men at lower risk. • Multiparametric MRI can be used in conjunction with the standard transrectal ultrasound (TRUS)-guided biopsy to improve detection of clinically significant cancers.
MGH Hotline 02.04.11 To promote awareness about the disease and the importance of self-exams, the MGH and CBS Cares are collaborating on a fun, informative public service announcement (PSA).
What to expect during admission for ambulatory procedures with short recovery time, allowing discharge that day.
What to expect during admission for a prostatectomy procedure. A prostatectomy is a surgical procedure to remove the prostate gland.
What to expect during admission for a nephrectomy procedure. A nephrectomy is a surgical procedure to remove all or part of the kidney. Surgery may involve one or both kidneys.
Back to Top